Proposal Status/Commentary

USP posts the status of Revisions, Deferrals, Cancellations, Commentary, and Index for each USP–NF and Supplement.

  • Revisions are approved standards that will appear in the publication.
  • Deferrals are items that have been proposed in Pharmacopeial Forum (PF) but are not yet approved by an Expert Committee.
  • Cancellations are items that have been proposed in PF but have been canceled. Canceled items may be re-proposed in a future PF.
  • Commentary is a summary of comments received and the appropriate Expert Committee's responses in cases when proposals advance to official status without being re-published in PF.
  • The Index is a copy of the combined Index for a given Book or Supplement. The Index is posted for informational use only and should not be used for interpretive purposes.

Revisions, Deferrals, and Cancellations generally are posted in advance of posting of the online USP–NF or Supplement. Commentary and Index are posted the same day the online USP–NF, Supplement, or other official text is released.

Now Available: 2015–2020 Cumulative List of USP–NF Revisions (updated 06–Aug–2020)

The Cumulative List of USP–NF Revisions provides updated information on all items approved, deferred, or cancelled during the 2015–2020 Cycle.

Interim Revision Announcements

As of First Supplement to USP 43–NF 38, IRAs are no longer associated with a print publication and are immediately available on USP–NF Online.

IRAs published in PF 46(2)

IRAs published in PF 46(1)

No new IRAs were published for comment in PF 46(1)

IRAs published in PF 45(6)

IRAs published in PF 45(5)

  • No new IRAs were published for comment in PF 45(5)

IRAs published in PF 45(4)

IRAs published in 45(3)

IRAs published in 45(2):

  • Deferrals: Atropine Sulfate Ophthalmic Solution
  • Cancellations: None
  • Commentary: None

IRAs published in 45(1):

  • Deferrals: Glycine 
  • Cancellations: None
  • Commentary: None

      USP 43–NF 38

      Supplement 2

      Supplement 1

      Due to the extended comment period for Pharmacopeial Forum 45(1), it will be included in the publication for Supplement 1 instead of that for USP–NF.

      Book

      IRAs published in 44(6)

      • There were no IRAs published for comment in 44(6)

      USP 42–NF 37

      Supplement 2

      IRAs published for comment in PF 44(4)

      • Deferrals: None
      • Cancellations: None
      • Commentary: None

      IRAs published for comment in PF 44(5)

      • Deferrals: None
      • Cancellations: None
      • Commentary: None

      Supplement 1

      IRAs published in PF 44(2)

      • No IRAs were published for comment in PF 44(2)

      IRAs published in PF 44(3)

      • No IRAs were published for comment in PF 44(3)

      Book

      IRAs in PF 44(1)

      • No IRAs were published for comment in PF 44(1)

      IRAs in PF 43(6)

      • No IRAs were published for comment in PF 43(6)

      USP 41–NF 36

      Supplement 2

      IRAs in PF 43(5)

      • Deferrals: None
      • Cancellations: None
      • Commentary: None

      IRAs in PF 43(4)

      • No IRAs were published for comment in PF 43(4)

      Supplement 1

      IRAs in PF 43(3)

      • No IRAs were published for comment in PF 43(3)

      IRAs in PF 43(2)

      • Deferrals: Valine
      • Cancellations: None
      • Commentary: PF 43(2) (updated 26–Jan–2018) 

      Book

      IRAs in PF 43(1)

      • Deferrals: None
      • Cancellations: None
      • Commentary: PF 43(1)

      IRAs in PF 42(6)

      • Deferrals: None
      • Cancellations: None
      • Commentary: PF 42(6)

      USP 40–NF 35

        USP 39–NF 34

        USP 38–NF 33

        USP 37–NF 32

        USP 36–NF 31

        USP 35–NF 30

        USP 34–NF 29

        USP 33–NF 28

        USP 32–NF 27

        USP 31–NF 26

        USP 30–NF 25